April 10, 2018 / 12:20 AM / a year ago

Samsung C&T says no plan currently to buy a stake in biopharma affiliate

FILE PHOTO: Employees are reflected on a logo of Samsung C&T Corp at the company's headquarters in Seoul, South Korea, July 16, 2015. REUTERS/Kim Hong-Ji

SEOUL (Reuters) - Samsung C&T Corp (028260.KS) said on Tuesday it has no plan currently to purchase shares in Samsung Bioepis Co, after a report said the company is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in its biopharma affiliate.

“Samsung C&T is reviewing various measures to secure growth engine for the future, but the firm is not planning at the moment to buy a stake in Samsung Bioepis,” Samsung C&T said in a statement.

Reporting by Haejin Choi; Editing by Hyunjoo Jin; Editing by Muralikumar Anantharaman

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below